These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26403989)

  • 1. A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients.
    Arain SQ; Talpur FN; Channa NA
    Lipids Health Dis; 2015 Sep; 14():117. PubMed ID: 26403989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipid profile as a marker of liver impairment in hepatitis B Cirrhosis patients.
    Arain SQ; Talpur FN; Channa NA; Ali MS; Afridi HI
    Lipids Health Dis; 2017 Mar; 16(1):51. PubMed ID: 28249586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum lipids as an indicator for the alteration of liver function in patients with hepatitis B.
    Arain SQ; Talpur FN; Channa NA; Ali MS; Afridi HI
    Lipids Health Dis; 2018 Mar; 17(1):36. PubMed ID: 29506525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Predictive value of a rapid negativity of serum virus C viremia during treatment with interferon alpha in patients with chronic hepatitis C].
    Moulin V; Harzic M; Doll J; Dubeaux B; Ghnassia JC; Andrieu J
    Pathol Biol (Paris); 1996 May; 44(5):468-72. PubMed ID: 8758497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.
    De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Raiteri R; Di Perri G
    J Antimicrob Chemother; 2006 Feb; 57(2):360-3. PubMed ID: 16396921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
    Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
    J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients.
    Cesari M; Caramma I; Antinori S; Adorni F; Galli M; Milazzo L
    HIV Med; 2009 Oct; 10(9):580-5. PubMed ID: 19785667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial quantitation of serum core protein and viral RNA of hepatitis C virus after interferon therapy: increase in viral loads in biochemical responders.
    Yoshioka K; Aiyama T; Iwata K; Yano M; Okumura A; Ishikawa T; Kakumu S
    Am J Gastroenterol; 1997 Aug; 92(8):1305-9. PubMed ID: 9260795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C.
    Liu CH; Liang CC; Liu CJ; Lin JW; Chen SI; Hung PH; Tsai HB; Lai MY; Chen PJ; Chen DS; Kao JH
    Clin Infect Dis; 2010 Sep; 51(5):541-9. PubMed ID: 20645865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
    Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
    Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
    Harrison SA; Abdurakhmanov D; Shiffman ML; Bakulin I; Mazur W; Rodriguez-Torres M; Silva GF; Cheinquer H; Messinger D; Connell EV; McKenna M; Tatsch F; Reddy KR;
    J Clin Gastroenterol; 2013 Mar; 47(3):271-9. PubMed ID: 22951527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.